Profile data is unavailable for this security.
About the company
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
- Revenue in USD (TTM)25.47m
- Net income in USD-15.63m
- Incorporated2001
- Employees62.00
- LocationMolecular Templates Inc9301 Amberglen Blvd, Suite 100AUSTIN 78729-1153United StatesUSA
- Phone+1 (512) 896-1555
- Fax+1 (302) 655-5049
- Websitehttps://www.mtem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 1.73m | 51.00 | -- | -- | -- | 0.0867 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -19.42m | 1.79m | 5.00 | -- | 0.2703 | -- | -- | -879.07 | -879.07 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -109.68 | -- | -338.60 | -- | -- | -- | -- | -- | -- | -- | 0.0935 | -- | -- | -- | 3.02 | -- | -- | -- |
| Aclarion Inc | 53.95k | -5.90m | 1.83m | 6.00 | -- | 0.879 | -- | 33.99 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -8.59m | 1.95m | 10.00 | -- | 0.1752 | -- | -- | -1,401.07 | -1,401.07 | 0.00 | 20.09 | 0.00 | -- | -- | 0.00 | -103.48 | -- | -134.72 | -- | -- | -- | -- | -- | -- | -12.38 | 0.002 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -4.99m | 1.97m | 2.00 | -- | 0.6751 | -- | -- | -8.19 | -8.19 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -81.44 | -69.27 | -110.87 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.1011 | -- | -- | -- | 60.32 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -29.11m | 2.12m | 7.00 | -- | -- | -- | -- | -0.5892 | -0.5892 | 0.00 | -2.54 | 0.00 | -- | -- | 0.00 | -90.03 | -83.69 | -119.01 | -97.54 | -- | -- | -- | -- | -- | -14.34 | 11.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Entero Therapeutics Inc | 0.00 | -8.15m | 2.16m | 15.00 | -- | 0.2568 | -- | -- | -6.31 | -6.81 | 0.00 | 14.77 | 0.00 | -- | -- | 0.00 | -17.27 | -295.92 | -21.53 | -1,599.51 | -- | -- | -- | -- | -- | -3,009.98 | 0.00 | -- | -- | -- | -7.55 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 2.16m | 3.00 | 1.47 | -- | 85.22 | 7.69 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 2.21m | 62.00 | -- | 0.3105 | -- | 0.0867 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Cyclacel Pharmaceuticals Inc | 74.00k | -13.48m | 2.24m | 12.00 | -- | -- | -- | 30.25 | -9.12 | -9.12 | 0.0168 | -0.4507 | 0.0083 | -- | 0.0392 | -- | -150.25 | -57.58 | -794.97 | -69.81 | -- | -- | -18,150.00 | -18,789.29 | -- | -45.03 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Qrons Inc | 0.00 | -393.67k | 2.31m | 2.00 | -- | -- | -- | -- | -0.0288 | -0.0288 | 0.00 | -0.0924 | 0.00 | -- | -- | 0.00 | -8,475.14 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.51m | 2.41m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 55.89k | -7.99m | 2.50m | 12.00 | -- | 0.7425 | -- | 44.66 | -24.17 | -24.17 | 0.1156 | 4.01 | 0.0071 | -- | 0.0881 | 4,657.50 | -100.88 | -- | -255.30 | -- | -- | -- | -14,287.67 | -- | -- | -331.07 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.42m | 2.61m | 8.00 | -- | 0.4785 | -- | -- | -15.06 | -15.06 | 0.00 | 5.16 | 0.00 | -- | -- | 0.00 | -96.33 | -71.92 | -122.03 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
Data as of Nov 25 2024. Currency figures normalised to Molecular Templates Inc's reporting currency: US Dollar USD
40.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bellevue Asset Management AGas of 30 Sep 2024 | 1.28m | 19.44% |
| SilverArc Capital Management LLCas of 30 Sep 2024 | 623.84k | 9.48% |
| BVF Partners LPas of 30 Sep 2024 | 522.24k | 7.93% |
| BMO Asset Management Corp.as of 30 Sep 2024 | 73.13k | 1.11% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 49.89k | 0.76% |
| Geode Capital Management LLCas of 30 Sep 2024 | 47.23k | 0.72% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 38.13k | 0.58% |
| Invst LLCas of 30 Sep 2024 | 23.40k | 0.36% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 14.05k | 0.21% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 13.68k | 0.21% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
